Biologically active additive "pressure plus for prophylaxis and maintenance therapy for hypotonia and vegetative-vascular dystonia

 

The invention relates to medicine, in particular to the pharmaceutical industry for the production of drugs therapeutic and prophylactic purposes, and can be used for the prevention and adjuvant therapy of hypotension and vascular dystonia. The proposed biologically active additive "Pressure plus" contains in its composition of red wines and food processing plants, while the BAD contains red wine in the form of dry concentrate of the extract, and food processing plants in the form of dry concentrate of Rhaponticum and dry concentrate of the extract of Rhodiola rosea, dry concentrate decoction of coffee, and cinnamon, dry concentrate infusions of pantocrine, oats, starch, sugar, calcium stearate and talc at a ratio of components a tablet weight of 0.55, Supplement stimulates circulation, has a vessel restorative effect without any side effect. table 2.

The invention relates to medicine, in particular to the pharmaceutical industry for the production of drugs therapeutic and prophylactic purposes, and can be used for the prevention and adjuvant therapy of hypotension their food Supplement. Almaty, Leovic, 2000, S. 139/ - the drug, which is a complex, stabilizing blood pressure, strengthens the circulatory system. Used with dystonia, migraine headaches, General weakness, hypotonia, morning sickness. The drug contains garlic, chilli peppers, canadian Hydrastis, leaf parsley, ginger root, Siberian ginseng root.

The disadvantage of the drug is observed in individual patients, individual intolerance to some of the components of the drug.

Known BAD "Creteil solution"/Pilate T. L. (ed) Federal register of biologically active additives to food. Moscow, Kohelet, 2001, S. 236/ - drug for prevention and reducing the risk of cardiovascular disease, improves heart function. The BAD contains red wine, and food processing plants: flowers and berries of hawthorn, leaves of a black currant, herb balm. Available in liquid form, packaged in bottles.

The disadvantage of the drug is observed in individual patients, individual intolerance to some of the components of the drug.

The objective of the invention is to develop a new affordable medicines youdim, increasing blood pressure, normalizing the circulation of blood, cardiac and vessel restorative effect.

The invention is aimed at expanding Arsenal of drugs for the prevention and treatment of hypotension and vascular dystonia.

This is achieved by the fact that dietary Supplement as well as well-known medication contains red wine, and food processing plants.

However, in contrast to known drug proposed dietary Supplement includes red wine in the form of a dry concentrate and food processing plants in the form of dry concentrate of the extract of Rhaponticum and Rhodiola rosea, in addition, it contains a dry concentrate decoction of coffee, cinnamon, dry concentrate infusions of pantocrine, oats, starch, sugar, calcium stearate and talc in the following ratio of components a tablet weight of 0.55 g, g: Dry concentrate of red wine - 0,00015-0,0016 Dry concentrate of the extract of Rhaponticum - is 0.0002-0,0016 Dry concentrate of the extract of Rhodiola rosea - is 0.0002-0,0016 Dry concentrate infusions of pantocrine - 0,00009-0,0007 Dry concentrate decoction of coffee 0,000008-of 0.00006 Cinnamon - 0,0050-0,0400 Oats - 0,0250-0,1000 Starch - 0,0400-0,1000 calcium Stearate - 0,0025-0,0200
Talc - 0,0025-0,0200
Sugar "Pressure plus" appears in a stimulating, tonic, increases blood pressure, normalizing the circulation of blood, cardiac and sosudoukreplyayuschim action; regulates heart rate, vascular tone, and improves overall organ hemodynamics.

SUPPLEMENTS used for prevention and adjuvant therapy for hypotonia and dystonia.

The invention is illustrated by the following example.

Biologically active food Supplement "Pressure plus" in the form of tablets obtained as follows.

The sugar in the number 72,8 kg weighed, visually check for the presence of mechanical impurities, then in the absence of impurities crushed in the mill. For this sugar load portions in the hopper. Powdered sugar through the bottom fitting of the mill gathering into a polyethylene bag, the ends of which are pre-fixed to the fitting. The bag is placed in the receiver.

The output of crushed sugar 72,0 kg

Oats in the amount of 10.4 kg weigh the bag on the scale, visually check for the presence of mechanical impurities, then in the absence of impurities crushed in the mill. For this purpose, oats load portions in the hopper.

Crushed oats through the bottom fitting of the mill is collected in bold crushed oats 10,3 kg

The bark of the cinnamon in the amount of 2 kg weighed, visually check for the presence of mechanical impurities, then in the absence of impurities crushed in the mill. The cinnamon bark load portions in the hopper. The crushed bark of the cinnamon through the lower fitting in the plastic bag, the ends of which are pre-fixed to the fitting. The bag is placed in the receiver.

The output of crushed cinnamon bark 1,9 kg

Coffee beans in amounts of 0.2 kg weighed, visually check for the presence of mineral and organic impurities, then in the absence of impurities crushed in the mill. To do this, the coffee beans are downloading portions in the hopper. Crushed coffee beans through the bottom fitting of the mill gathering into a polyethylene bag, the ends of which are pre-fixed to the fitting. The bag is placed in the receiver.

The output of coffee 0,19.

0,19 kg of milled coffee is loaded into enamel container and pour the purified water at room temperature in the amount of 2.5 kg, the mixture is soaked in a boiling water bath for 25 minutes with frequent stirring. Cool 45 minutes at room temperature. Broth (1.5% of dry) filter, wringing out coffee grounds. If necessary, add water to desired the boil 2 kg of broth coffee. Separately mix 0.16 kg of starch and 0.3 kg of a decoction of coffee, the mixture is stirred and added to the boiling solution with constant stirring, bring to a boil.

The output of starch paste 2,45 kg

Powdered sugar, oats, cinnamon, starch is sifted through a sieve with the hole diameter of 1 mm, calcium stearate is sifted through a sieve with the hole diameter of 1 mm, the powder is sifted through a sieve with the hole diameter of 0.5 mm, an extract of Rhaponticum carthamoides extract, Rhodiola rosea, pantocrine, water, red wine is filtered through 4 layers of gauze.

In a mixer with the cover open load 22 kg powdered sugar and 1.9 kg of cinnamon, the mixture is stirred for 3 minutes, then make the starch in the amount of 16.69 per kg, oats 10,3 kg and remaining sugar. The mixture is stirred for 10 minutes. Then moisturize pharmacopeial extract (4% dry) of Rhodiola rosea in the amount of 3.8 kg, red wine (1.5% of dry) 3.8 kg, stirred for 10 minutes, then moisturize pharmacopeial extract (4% dry) Rhaponticum carthamoides in the amount of 1.9 kg and pharmacopeias tincture (3,5% of dry) pantocrine 1,9 kg the Mixture is stirred for 5 minutes, add starch paste 2,45 kg and again stirred for 10 minutes.

The product yield 114,74 kg

The wet mass in the number 114,74 kg push through us is Assu in the number 114,74 kg laid out on paper in the trays with a layer thickness of 1,5-2 see Trays set in a drying Cabinet. Include hot air distribution device of the drying Cabinet. Set the drying temperature 40-45oWith the increase of which the flow of hot air is automatically disabled. The drying process is carried out for 10 hours to a constant weight, with occasional stirring (not less than 3 times). The control end of the drying conduct in the laboratory by weighing samples of the product from the trays to a constant weight. The humidity of the product is not more than 2%. Dry tablet weight is directed to a dry granulation.

The output of the dry tablet weight 101,05 kg

The dried mixture in an amount of 101,05 kg loaded into the device for producing granules from dry tablespace. Include a screw device, in which the mixture is forced through a mesh with holes of diameter 1.5 to 2.0 mm, the Dry granulate is collected in the receiver. From the receiver the dry granulate load when the cover is open in the mixer. To the dry granulated pellet mixture in the mixer and add the sifted calcium stearate in an amount of 1.03 kg and talc 1,03 kg Include a mixer and stirred for 5 minutes. The finished granulate is passed on tableting.

The output of the granulate 102,0 kg

And the ut engine. Pre-set engine speed in accordance with a bulk weight of the pressing zone and the height of the tablet. When you start the machine turn on a vacuum cleaner.

The tablet diameter 12,00,2 mm

The height of the tablet 3,80,2 mm

The average weight of the tablets 0,550,03,

During tabletting watching the machine work and quality tablets. Every 30 minutes check raspadaemost, the strength and the average weight of the tablets. Tablets that do not meet the requirements, rejected and sent for reprocessing. At the end of the process the machine off in the reverse order. Tablets are collected in the receiver and sent to the dust.

The yield of 101.5 kg

The finished tablets are sieved by the vibrating screen through a hole diameter of 8 mm, weighed 8 kg and load in a clean dry plastic bucket. Samples of finished tablets passed into the analytical laboratory for analysis. In accordance tablets norms technical documentation prepared tablets passed the stage of packing.

The output of finished tablets 100 kg.

The sequence of operations is the same, regardless of the number of prepared composition.

BAD D is that in the specified combination (see table. I Examples 1-4) have stimulating, toning, increasing blood pressure, normalizing the circulation of blood, cardiac and vessel restorative effect.

As auxiliary components, ensuring reliability maintain the shape of the pressed pellets in a dry form and a short time raspadaemosti them in a humid environment, used sugar and starch, to improve the fluidity of the granular and increase the strength of the pressing - calcium stearate and talc.

Tablet form is easy to use and has a long shelf life (2 years).

Clinical studies BAD "Pressure plus" was carried out in the outpatient clinic 16 Eastern administrative district of Moscow. The aim of the study was a clinical study of the effect of BAD Pressure plus the level of blood pressure in arterial hypotonia of different Genesis, as well as to physical and mental health.

Surveyed 20 people (10 women and 10 men), working age from 25 to 58 years (mean age 42,2of 6.7 years) with arterial hypertension on the background of vegetative-vascular dystonia of hypotonic type (13), including exacerbation and severe tenesaca and (1), pneumonia (1), chronic pyelonephritis (2). In 2 people hypotension was due to asthenic syndrome after previous abdominal operations, 5 elderly was observed on the background of CHD (with postinfarction cardiosclerosis).

Check all symptoms of patients was performed according to the Protocol of the study on the day of treatment. Received SUPPLEMENTS "Pressure plus in the dose of 2 tablets 3 times a day for 30 days, with control through 14 days. Dynamics of symptoms were recorded in maps observations and evaluated in conventional points on a five-point scale, was estimated common symptoms of asthenia (fatigue, irritability, emotional lability), was given a self-assessment of physical and mental health. Registered HELL.

In the treatment of all patients has not been used for other forms of adaptogenic and vitamin-mineral preparations.

The control group consisted of 10 patients, matched for age and nature of the pathology treated with tincture of Siberian ginseng.

Before therapy SUPPLEMENTS "Pressure plus hypotension (average 90/50 mm RT.CT.) it was noted in 100% of patients. Complaints of weakness, fatigue, increased irritability, emotional, La is e) his physical and intellectual performance in average to 1.7 srvc. score (on a 5-point scale). Against the backdrop of the BAD complaints of weakness and fatigue already to 14 days of administration significantly decreased, which correlated with reduction of arterial hypotension in 70% (14) patients, confirmed by repeated measurements (table 2).

Self-assessment of physical and mental health was progressively increased in the dynamics from the 14 th to the 30 th day of taking SUPPLEMENTS. Patients in the control group treated with tincture of Siberian ginseng, in 60% of cases remained hypotension, though to a lesser extent than for initial registration.

Thus, the use of parapharmaceutical "Pressure plus proved sufficient clinical efficacy in patients with asthenia regardless of the etiology of this condition.

Thus:
1. BAD Pressure plus" is a tonic, objectively increases the blood pressure for hypotension, improving the overall condition of the patients.

2. BAD Pressure plus may be used as an effective tool in the integrated treatment of vegetative-vascular dystonia of hypotonic type and asthenic States.

3. In the process of applying BAD allergic reactions and side effects not registracii and supportive therapy for hypotension in dystonia, includes red wine and products of processing of medicinal plants, characterized in that it contains red wine in the form of a dry concentrate and food processing plants in the form of dry concentrate of the extract of Rhaponticum and Rhodiola rosea, dry concentrate decoction of coffee, and cinnamon, dry concentrate infusions of pantocrine, oats, starch, sugar, calcium stearate and talc in the following ratio of components a tablet weight of 0.55 g, g:
Dry concentrate of red wine - 0,00015-0,0016
Dry concentrate of the extract of Rhaponticum - is 0.0002-0,0016
Dry concentrate of the extract of Rhodiola rosea - is 0.0002-0,0016
Dry concentrate decoction of coffee 0,000008-of 0.00006
Cinnamon - 0,0050-0,0400
Dry concentrate infusions of pantocrine - 0,00009-0,0007
Oats - 0,0250-0,1000
Starch - 0,0400-0,1000
Calcium stearate - 0,0025-0,0200
Talc - 0,0025-0,0200
Sugar - Ostalnoe

 

Same patents:

The invention relates to pharmaceutical compositions containing the inhibitor nm g COA reductase (E.)-7-[4-(4-forfinal)-6-isopropyl-2-[methyl(methylsulphonyl)amino] pyrimidine-5-yl]-(3R, 5S)-3,5-dihydroxide-6-envoy acid or its pharmaceutically acceptable salt as an active ingredient

The invention relates to the field of medicine and relates to a method of increasing the expression of molecular chaperone cell and/or increasing the activity of molecular chaperones in cells by treating the cells an effective amount of hydroxylamine derivative of the formula (I) or (II), as well as to new derivatives of hydroxylamine and farmkompanijam based on them
The invention relates to medicine, in particular to pharmaceutical drugs used in cardiovascular diseases

The invention relates to pharmaceutical industry
The invention relates to medicine, specifically to the preparations for the prevention and treatment of various forms of ischemic heart disease, atherosclerosis, and acute circulatory disorders, cerebral stroke

The invention relates to a group of compounds of General formula (I) high degree of purification

The invention relates to compositions and methods designed to reduce the concentration of cholesterol low-density lipoprotein (LDL) and total concentration of cholesterol in the blood

The invention relates to new derivatives of xanthine with integral aminirovanie alkanolamine the side chains of the formula I in the form of individual stereoisomers or as mixtures of stereoisomers, has a neuroprotective effect
The invention relates to medicine, specifically to the creation of a plant for the treatment of postinfarction cardiosclerosis and method of its use

The invention relates to medicine, in particular to the pharmaceutical industry for the production of drugs therapeutic and prophylactic purposes, and can be used as an auxiliary tonic and mild sedative

The invention relates to medicine, in particular to the drug based on an extract of motherwort, intended for the treatment of functional disorders of the Central nervous system

The invention relates to medicine

The invention relates to pharmaceutical compositions containing the inhibitor nm g COA reductase (E.)-7-[4-(4-forfinal)-6-isopropyl-2-[methyl(methylsulphonyl)amino] pyrimidine-5-yl]-(3R, 5S)-3,5-dihydroxide-6-envoy acid or its pharmaceutically acceptable salt as an active ingredient
The invention relates to medicine, in particular to pharmaceutical drugs used in cardiovascular diseases

The invention relates to medicine, in particular to the pharmaceutical industry for the production of drugs therapeutic and prophylactic purposes, and can be used as a tonic that improves the health and the body's resistance to adverse environmental factors

The invention relates to medicine, namely to the pharmaceutical industry for the production of drugs therapeutic and prophylactic purposes, and can be used for the prevention and auxiliary treatment of gastritis, duodenitis and colitis of various etiologies, peptic ulcer
The invention relates to medicine, in particular chemical-pharmaceutical industry, such as medications, used to treat fungal diseases, namely candidiasis of the gastrointestinal tract, intestinal kandidonoshitelstvo, candidiasis internal organs, chronic granulomatous and disseminated forms of candidiasis, koktsidioidoze, cryptococcosis, blastomycosis, in addition, successfully used in the treatment of pnevmatikatos, Candida nasopharynx and other fungal diseases

The invention relates to the field of medicine and concerns antihistamine medications

The invention relates to medicine and relates to tools having a hepatoprotective effect
Up!